AstraZeneca: UBS upgrades stock
(CercleFinance.com) - UBS has upgraded the AstraZeneca stock from Neutral to Buy, having raised its target price from 11,500 pence to 14,200 pence, which now represents 22% upside potential.
We are upgrading AstraZeneca from Neutral to Buy, in line with our PharmaValues 2025 strategic conclusions, UBS says.
AstraZeneca posted FY total sales of $54bn, up 18% (+21% at constant exchange rates), with EPS of $4.54 (+18% as reported, +29% at constant exchange rates) and core EBIT of $8.21 (13% as reported, +19% at constant exchange rates).
For 2025, AstraZeneca expects total sales to increase by a high single-digit percentage, with core EPS up a low double-digit percentage.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
We are upgrading AstraZeneca from Neutral to Buy, in line with our PharmaValues 2025 strategic conclusions, UBS says.
AstraZeneca posted FY total sales of $54bn, up 18% (+21% at constant exchange rates), with EPS of $4.54 (+18% as reported, +29% at constant exchange rates) and core EBIT of $8.21 (13% as reported, +19% at constant exchange rates).
For 2025, AstraZeneca expects total sales to increase by a high single-digit percentage, with core EPS up a low double-digit percentage.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.